

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

GZMK (granzyme K (granzyme 3; tryptase II)) Antibody (against the N terminal of GZMK) (50ug)

RRID:AB_1294297

Type: Antibody

Proper Citation

Aviva Systems Biology Cat# ARP45219_P050, RRID:AB_1294297

Antibody Information

URL: http://antibodyregistry.org/AB_1294297

Proper Citation: Aviva Systems Biology Cat# ARP45219_P050, RRID:AB_1294297

Target Antigen: GZMK (granzyme K (granzyme 3; tryptase II)) (against the N terminal of GZMK) (50ug)

Host Organism: rabbit

Clonality: polyclonal

Comments: manufacturer recommendations: WB; ELISA; Western Blot

Antibody Name: GZMK (granzyme K (granzyme 3; tryptase II)) Antibody (against the N terminal of GZMK) (50ug)

Description: This polyclonal targets GZMK (granzyme K (granzyme 3; tryptase II)) (against the N terminal of GZMK) (50ug)

Target Organism: porcine, pig, human

Antibody ID: AB_1294297

Vendor: Aviva Systems Biology

Catalog Number: ARP45219_P050

Record Creation Time: 20250819T233849+0000

Record Last Update: 20250820T055937+0000

Ratings and Alerts

No rating or validation information has been found for GZMK (granzyme K (granzyme 3; tryptase II)) Antibody (against the N terminal of GZMK) (50ug).

No alerts have been found for GZMK (granzyme K (granzyme 3; tryptase II)) Antibody (against the N terminal of GZMK) (50ug).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yang X, et al. (2024) Single-Cell Analysis Identifies Distinct Populations of Cytotoxic CD4+ T Cells Linked to the Therapeutic Efficacy of Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma. Journal of inflammation research, 17, 4505.